Skip to main content

Table 3 Relationships between lipid metabolism and immune activity

From: Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy

 

ALC (pre-NAC)

NLR (pre-NAC)

ALC (post-NAC)

NLR (post-NAC)

Low

High

P value

Low

High

P value

Low

High

P value

Low

High

P value

All breast cancer (n = 327)

TC (preNAC)

  

0.638

  

0.479

  

0.564

  

0.978

 Normal

82 (56.9%)

79 (54.1%)

 

76 (53.2%)

85 (57.8%)

 

145 (56.2%)

15 (50.0%)

 

59 (55.7%)

101 (55.5%)

 

 High

62 (43.1%)

67 (45.9%)

 

67 (46.8%)

62 (42.2%)

 

113 (43.8%)

15 (50.0%)

 

47 (44.3%)

81 (44.5%)

 

TG (preNAC)

  

0.249

  

0.886

  

0.101

  

0.655

 Normal

117 (81.8%)

110 (75.9%)

 

112 (79.4%)

115 (78.2%)

 

205 (80.1%)

20 (66.7%)

 

81 (77.1%)

144 (79.6%)

 

 High

26 (18.2%)

35 (24.1%)

 

29 (20.6%)

32 (21.8%)

 

51 (19.9%)

10 (33.3%)

 

24 (22.9%)

37 (20.4%)

 

TC (postNAC)

  

0.388

  

0.219

  

0.292

  

0.163

 Normal

60 (47.6%)

59 (41.8%)

 

60 (41.1%)

59 (48.8%)

 

105 (43.8%)

14 (56.0%)

 

51 (50.5%)

68 (41.5%)

 

 High

66 (52.4%)

82 (58.2%)

 

86 (58.9%)

62 (51.2%)

 

135 (56.2%)

11 (44.0%)

 

50 (49.5%)

96 (58.5%)

 

TG (postNAC)

  

0.001

  

0.164

  

0.803

  

0.974

 Normal

81 (68.6%)

63 (46.7%)

 

73 (52.9%)

71 (61.7%)

 

129 (56.8%)

13 (54.2%)

 

55 (56.7%)

87 (56.5%)

 

 High

37 (31.4%)

72 (53.3%)

 

65 (47.1%)

44 (38.3%)

 

98 (43.2%)

11 (45.8%)

 

42 (43.3%)

67 (43.5%)

 

Luminal (n = 108)

TC (preNAC)

  

0.54

  

0.838

  

0.728

  

0.665

 Normal

25 (58.1%)

27 (50.9%)

 

28 (52.8%)

24 (55.8%)

 

48 (55.2%)

4 (44.4%)

 

16 (50.0%)

36 (56.3%)

 

 High

18 (41.9%)

26 (49.1%)

 

25 (47.2%)

19 (44.2%)

 

39 (44.8%)

5 (55.6%)

 

16 (50.0%)

28 (43.7%)

 

TG (preNAC)

  

0.801

  

0.801

  

0.915

  

0.064

 Normal

35 (81.4%)

41 (77.4%)

 

41 (77.4%)

35 (81.4%)

 

69 (79.3%)

7 (77.8%)

 

29 (90.6%)

47 (73.4%)

 

 High

8 (18.6%)

12 (22.6%)

 

12 (22.6%)

8 (18.6%)

 

18 (20.7%)

2 (22.2%)

 

3 (9.4%)

17 (26.6%)

 

TC (postNAC)

  

0.853

  

0.667

  

0.926

  

0.38

 Normal

15 (36.6%)

20 (38.5%)

 

20 (35.7%)

15 (40.5%)

 

31 (37.8%)

4 (36.4%)

 

16 (44.4%)

19 (33.3%)

 

 High

26 (63.4%)

32 (61.5%)

 

36 (64.3%)

22 (59.5%)

 

51 (62.2%)

7 (63.6%)

 

20 (55.6%)

38 (66.7%)

 

TG (postNAC)

  

0.397

  

0.386

  

0.515

  

0.661

 Normal

25 (64.1%)

28 (54.9%)

 

34 (63.0%)

19 (52.8%)

 

45 (57.0%)

8 (72.7%)

 

22 (62.9%)

31 (56.4%)

 

 High

14 (35.9%)

23 (45.1%)

 

20 (37.0%)

17 (47.2%)

 

34 (43.0%)

3 (27.3%)

 

13 (37.1%)

24 (43.6%)

 

Luminal-HER (n = 42)

TC (preNAC)

  

0.176

  

0.491

  

0.135

  

0.774

 Normal

13 (72.2%)

8 (47.1%)

 

10 (52.6%)

11 (68.8%)

 

19 (65.5%)

1 (20.0%)

 

9 (56.3%)

11 (61.1%)

 

 High

5 (27.8%)

9 (52.9%)

 

9 (47.4%)

5 (31.2%)

 

10 (34.5%)

4 (80.0%)

 

7 (43.7%)

7 (38.9%)

 

TG (preNAC)

  

0.695

  

0.114

  

0.868

  

0.7

 Normal

14 (73.7%)

14 (82.4%)

 

17 (89.5%)

11 (64.7%)

 

23 (76.7%)

4 (80.0%)

 

13 (81.3%)

14 (73.7%)

 

 High

5 (26.3%)

3 (17.6%)

 

2 (10.5%)

6 (35.3%)

 

7 (23.3%)

1 (20.0%)

 

3 (18.7%)

5 (26.3%)

 

TC (postNAC)

  

0.462

  

0.715

  

0.96

  

0.837

 Normal

10 (58.8%)

5 (38.5%)

 

8 (57.1%)

7 (43.8%)

 

14 (51.9%)

1 (50.0%)

 

7 (53.9%)

8 (50.0%)

 

 High

7 (41.2%)

8 (61.5%)

 

6 (42.9%)

9 (56.2%)

 

13 (48.1%)

1 (50.0%)

 

6 (46.1%)

8 (50.0%)

 

TG (postNAC)

  

0.274

  

0.897

  

0.206

  

0.705

 Normal

11 (64.7%)

5 (41.7%)

 

7 (53.9%)

9 (56.3%)

 

15 (57.7%)

0 (0.00%)

 

6 (46.2%)

9 (60.0%)

 

 High

6 (35.3%)

7 (58.3%)

 

6 (46.1%)

7 (43.7%)

 

11 (42.3%)

2 (100.0%)

 

7 (53.8%)

6 (40.0%)

 

HER2-enriched (n = 72)

TC (preNAC)

  

0.955

  

0.935

  

0.738

  

0.935

 Normal

20 (60.6%)

19 (61.3%)

 

16 (61.5%)

23 (60.5%)

 

33 (62.3%)

6 (54.6%)

 

16 (61.5%)

23 (60.5%)

 

 High

13 (39.4%)

12 (38.7%)

 

10 (38.5%)

15 (39.5%)

 

20 (37.7%)

5 (45.4%)

 

10 (38.5%)

15 (39.5%)

 

TG (preNAC)

  

0.363

  

0.539

  

0.046

  

0.349

 Normal

26 (83.9%)

22 (73.3%)

 

20 (83.3%)

28 (75.7%)

 

42 (84.0%)

6 (54.6%)

 

18 (72.0%)

30 (83.3%)

 

 High

5 (16.1%)

8 (26.7%)

 

4 (16.7%)

9 (24.3%)

 

8 (16.0%)

5 (45.4%)

 

7 (28.0%)

6 (16.7%)

 

TC (postNAC)

  

0.593

  

0.787

  

0.697

  

0.267

 Normal

16 (66.7%)

20 (58.8%)

 

17 (58.6%)

19 (65.5%)

 

30 (60.0%)

6 (75.0%)

 

16 (72.7%)

20 (55.6%)

 

 High

8 (33.3%)

14 (41.2%)

 

12 (41.4%)

10 (34.5%)

 

20 (40.0%)

2 (25.0%)

 

6 (27.3%)

16 (44.4%)

 

TG (postNAC)

  

0.021

  

0.264

  

0.766

  

0.779

 Normal

18 (81.8%)

15 (48.4%)

 

14 (53.9%)

19 (70.4%)

 

29 (63.0%)

4 (57.1%)

 

13 (65.0%)

20 (60.6%)

 

 High

4 (18.2%)

16 (51.6%)

 

12 (46.1%)

8 (29.6%)

 

17 (37.0%)

3 (42.9%)

 

7 (35.0%)

13 (39.4%)

 

TNBC (n = 105)

TC (preNAC)

  

0.539

  

0.683

  

0.364

  

0.664

 Normal

24 (48.0%)

25 (55.6%)

 

22 (48.9%)

27 (54.0%)

 

45 (50.6%)

4 (80.0%)

 

18 (56.3%)

31 (50.0%)

 

 High

26 (52.0%)

20 (44.4%)

 

23 (51.1%)

23 (46.0%)

 

44 (49.4%)

1 (20.0%)

 

14 (43.7%)

31 (50.0%)

 

TG (preNAC)

  

0.22

  

0.462

  

0.287

  

0.034

 Normal

42 (84.0%)

33 (73.3%)

 

34 (75.6%)

41 (82.0%)

 

71 (79.8%)

3 (60.0%)

 

21 (65.6%)

53 (85.5%)

 

 High

8 (16.0%)

12 (26.7%)

 

11 (24.4%)

9 (18.0%)

 

18 (20.2%)

2 (40.0%)

 

11 (34.4%)

9 (14.5%)

 

TC (postNAC)

  

0.382

  

0.19

  

0.294

  

0.87

 Normal

19 (43.2%)

14 (33.3%)

 

15 (31.9%)

18 (46.2%)

 

30 (37.0%)

3 (75.0%)

 

12 (40.0%)

21 (38.2%)

 

 High

25 (56.8%)

28 (66.7%)

 

32 (68.1%)

21 (53.8%)

 

51 (63.0%)

1 (25.0%)

 

18 (60.0%)

34 (61.8%)

 

TG (postNAC)

  

0.008

  

0.025

  

0.353

  

0.817

 Normal

27 (67.5%)

15 (36.6%)

 

18 (40.0%)

24 (66.7%)

40 (52.6%)

1 (25.0%)

14 (48.3%)

27 (52.9%)

 

 High

13 (32.5%)

26 (63.4%)

 

27 (60.0%)

12 (33.3%)

36 (47.4%)

3 (75.0%)

15 (51.7%)

24 (47.1%)

 
  1. ALC, absolute lymphocyte count; HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; NLR, neutrophil-to-lymphocyte ratio; TC, total-cholesterol; TG, triglyceride; TNBC, triple-negative breast cancer